汇宇制药2024年年报显示，上海爽飒为公司第六大股东。 中国经济网北京5月12日讯汇宇制药(688553.SH)近日发布公告称，因自身资金需求，股东上海爽飒企业 管理咨询事务所(有限合伙)(以下简称"上海爽飒")拟通过集中竞价或大宗交易的方式减持公司股份不超 过12,695,629股，合计减持股份比例不超过公司股份总数的2.997%。减持期间为自公告披露之日起15个 交易日后的3个月内。 截至公告披露之日，公司股东上海爽飒持有公司股份数量为12,695,629股，占公司总股本的2.997%；上 述股份来源于公司首次公开发行前取得的股份，且已于2022年10月26日起解除限售并上市流通。 汇宇制药发行募集资金总额为24.72亿元，扣除发行费用后，募集资金净额为23.61亿元。汇宇制药最终 募集资金净额比原计划多4.53亿元。汇宇制药于2021年10月18日披露的招股书显示，公司拟募集资金 19.07亿元，分别用于汇宇欧盟标准注射剂产业化基地(二期)项目、汇宇创新药物研究院建设项目、补充 流动资金。 汇宇制药发行费用合计1.11亿元，其中中信建投证券、国都证券获得承销费9887.48万元。 2021年10月26日 ...

Group 1 - Baichuan Energy plans to reduce its shareholding by up to 26.82 million shares, accounting for 2% of the total share capital, due to personal investment and funding needs [1] - Jinhong Gas intends to distribute a cash dividend of 1.00 yuan per 10 shares, with the record date on May 15, 2025 [2] - Jiahe Meikang's shareholder plans to reduce its stake by up to 1% of the total share capital due to liquidity needs [2][3] Group 2 - Jiadu Technology will cancel 10.20 million repurchased shares, reducing its total share capital from 2.143 billion shares to 2.133 billion shares [4] - ILE Home's shareholder plans to reduce its stake by up to 154,250 shares, accounting for 0.4778% of the total share capital, due to funding needs [5] - Lai Yifen has fully removed related batches of its honey date dumpling products from shelves due to consumer health concerns [6][7] Group 3 - CATL's vice chairman Li Ping and spouse plan to donate 4.05 million shares to Fudan University for establishing a research fund, reducing Li Ping's shareholding from 4.58% to 4.48% [8] - Shuanghuan Transmission's shareholders completed their reduction plan, selling a total of 6.69 million shares, accounting for 0.789% of the total share capital [9] - Chengfei Integration reported no significant changes in its business operations or external environment despite stock price fluctuations [10] Group 4 - Guizhou Tire's controlling shareholder plans to increase its stake by no less than 50 million yuan and no more than 100 million yuan within six months [11] - *ST Youshu's application to revoke the delisting risk warning has been approved, and its stock will resume trading under a new name [13] - Jingwei Huikai's shareholders plan to reduce their stake by up to 3% of the total share capital due to funding needs [14] Group 5 - Hualan Biological's major shareholder plans to reduce its stake by up to 3% of the total share capital due to funding needs [15] - Huyou Pharmaceutical's shareholder plans to reduce its stake by up to 2.997% of the total share capital due to funding needs [16] - Dongpeng Holdings' shareholders plan to reduce their stake by up to 1.5% of the total share capital due to funding needs [17] Group 6 - Keleke's controlling shareholder plans to reduce its stake by up to 3% of the total share capital due to funding needs [18] - Dongfang Ocean's major shareholder plans to reduce its stake by 1% of the total share capital due to investor redemption requests [19] - Yisheng Shares reported a sales revenue of 141 million yuan from white feather chicken seedlings in April, with a year-on-year decrease of 7.28% [20] Group 7 - Qujiang Cultural Tourism's controlling shareholder's 12 million shares are set to be auctioned due to contractual disputes, representing 4.70% of the total share capital [21] - Duople's shareholder plans to reduce its stake by up to 123,800 shares, accounting for 2% of the total share capital, due to personal funding needs [22][23]

2连板万向钱潮：拟收购WAC100%股权，交易方案正在进一步磋商 万向钱潮公告，公司股票于5月8日、5月9日连续两个交易日收盘价格涨幅偏离值累计达到20.94％， 属于股票交易异常波动情况。公司拟通过发行股份及支付现金方式，购买Wanxiang America Corp.100%股权，并向不超过35名特定投资者发行股份募集配套资金。本次交易构成关联交易，预计 将构成重大资产重组，不构成重组上市。目前，公司及相关各方积极推进本次交易整体工作进程。本 次交易所涉及的尽职调查、审计、评估等各项工作正在推进中，交易方案正在进一步磋商，交易相关 方尚未签署正式交易文件。 3连板成飞集成：近期公司经营情况及内外部经营环境未发生重大变化 成飞集成公告，公司股票于5月8日、5月9日连续两个交易日内收盘价格涨幅偏离值累计超过20%， 属于股票交易异常波动情形。经核实，公司前期披露的信息不存在需要更正、补充之处，近期公司经 营情况及内外部经营环境未发生重大变化，公司、控股股东和实际控制人不存在关于公司的应披露而 未披露的重大事项。 曲江文旅：控股股东所持4.7%公司股份拟被拍卖 2025.05. 11 5月11日晚间，沪深两市多 ...

Group 1 - Wanxiang Qianchao plans to acquire 100% equity of Wanxiang America Corp through a combination of share issuance and cash payment, with the transaction constituting a major asset restructuring [3] - Chengfei Integration's stock price has shown abnormal fluctuations, but the company confirms that there have been no significant changes in its operational situation or external environment [4] - Qujiang Cultural Tourism's controlling shareholder is facing a court-ordered auction of 12 million shares, which represents 4.7% of the company's total equity, but this will not affect the company's operations or control [5] Group 2 - *ST Youshu will have its delisting risk warning lifted, and its stock name will change from "*ST Youshu" to "Youkeshu" starting May 13, 2025 [6] - Yisheng shares reported a sales revenue of 141 million yuan for April 2025, a year-on-year decrease of 7.28%, attributed to lower prices of small white feather broilers [8] - Guizhou Tire's controlling shareholder plans to increase its stake in the company by investing between 50 million to 100 million yuan over the next six months [10][11] Group 3 - Kelik plans to reduce its shareholding by up to 3%, equating to a maximum of 1,464,700 shares, through centralized bidding or block trading [12] - Huili Pharmaceutical's shareholder plans to reduce its stake by up to 2.997%, amounting to a maximum of 12,695,629 shares, within three months after the announcement [13]

证券代码：688553 证券简称：汇宇制药 公告编号：2025-036 四川汇宇制药股份有限公司 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 持公司股份不超过 12,695,629 股，合计减持股份比例不超过公司股份 总数的 2.997%。 减持期间为自本公告披露之日起 15 个交易日后的 3 个月内。 若减持计划实施期间公司有派息、送股、资本公积金转增股本、配股 等除权除息事项，减持股份数将进行相应调整。 ? 大股东持股的基本情况 截至本公告披露之日，四川汇宇制药股份有限公司(以下简称"公司") 股东上海爽飒企业管理咨询事务所（有限合伙）(以下简称"上海爽飒") 持有公司股份数量为 12,695,629 股，占公司总股本的 2.997%；上述股 份来源于公司首次公开发行前取得的股份，且已于 2022 年 10 月 26 日 起解除限售并上市流通。 ? 减持计划的主要内容 因自身资金需求，股东上海爽飒拟通过集中竞价或大宗交易的方式减 无。 三、控股股东或者实际控制人减持首发前股份 是否是控股 ...

证券代码：688553 证券简称：汇宇制药 公告编号：2025-036 四川汇宇制药股份有限公司 关于股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 因自身资金需求，股东上海爽飒拟通过集中竞价或大宗交易的方式减 持公司股份不超过 12,695,629 股，合计减持股份比例不超过公司股份 总数的 2.997%。 减持期间为自本公告披露之日起 15 个交易日后的 3 个月内。 若减持计划实施期间公司有派息、送股、资本公积金转增股本、配股 等除权除息事项，减持股份数将进行相应调整。 | 股东名称 | 上海爽飒企业管理咨询事务所（有限合伙） | | | | --- | --- | --- | --- | | | 控股股东、实控人及一致行动人 | □是 | √否 | | 股东身份 | 直接持股 5%以上股东 | □是 | √否 | | | 董事、监事和高级管理人员 | □是 | √否 | 一、减持主体的基本情况 1 上述减持主体过去 12 个月内减持股份情况：无。 二、减持计划的主要 ...

Group 1 - Yitong Century won a bid for a communication engineering construction service project from China Mobile, with a total bid amount of 228 million yuan (including tax) [1] - Zhiyuan New Energy plans to repurchase shares worth between 33 million and 66 million yuan, with a maximum repurchase price of 22.00 yuan per share [1] - GAC Group reported April automobile sales of 116,400 units, a year-on-year decrease of 12.66% [2] - JAC Motors reported April automobile sales of 30,764 units, a year-on-year decrease of 3.55% [3] Group 2 - Fosun Pharma's subsidiary received FDA approval for a clinical trial of a live biotherapeutic product aimed at treating androgenetic alopecia [4] - Liangxin Co. obtained multiple patent certificates, including 2 invention patents and 32 utility model patents [5] - Sainuo Medical's two products received medical device registration certificates in Mexico and Ecuador [5] - Huayu Pharmaceutical's two products received marketing approvals in France and Spain [6] Group 3 - Shengnong Development reported April sales revenue of 1.533 billion yuan, a year-on-year increase of 0.68% [6] - Hasi Lian's potassium chloride and sodium chloride injection passed the consistency evaluation [7] - Shapuaisi received approval for a supplemental application for levofloxacin eye drops [9] - Tianyu Biological reported April sales revenue of 59.32 million yuan from pig sales [10] Group 4 - *ST Weihai was pre-awarded a project worth 108 million yuan [12] - Luoniushan reported April sales revenue of 125 million yuan from pig sales, a year-on-year increase of 12.72% [13] - Minhe Co. reported April sales revenue of 68.30 million yuan from chick sales, a year-on-year increase of 0.51% [14] Group 5 - Double Ring Technology's application for a specific stock issuance was approved by the Shenzhen Stock Exchange [15] - Hualu Hengsheng plans to repurchase shares worth between 200 million and 300 million yuan [16] - Baolong Technology plans to repurchase shares worth between 100 million and 200 million yuan [17] Group 6 - Huasheng Technology's subsidiary plans to sell shares of a company for 200 million yuan [24] - *ST Gengxing's controlling shareholder plans to increase holdings worth between 30 million and 60 million yuan [25] - Ruihuatai's shareholder plans to reduce holdings by up to 1% of the company's shares [26] Group 7 - Foton Motor reported April commercial vehicle sales of 54,816 units, a year-on-year increase of 21.63% [20] - China Merchants Bank plans to invest 15 billion yuan to establish a financial asset investment company [22] - Jinchengxin plans to invest approximately 231 million USD in the Alacran copper-gold-silver mine project [23] Group 8 - Zhongji United's controlling shareholder plans to reduce holdings by up to 2% of the company's shares [30] - Ningbo Huaxiang signed a strategic cooperation agreement to strengthen collaboration in various areas [31] - SMIC reported a net profit of 1.356 billion yuan for Q1 2025, a year-on-year increase of 166.5% [32] Group 9 - FAW Fuwi received a project notification to develop seat products for a luxury brand, with a total sales amount expected to be 1.39 billion yuan [33] - Huakang Clean won a bid for a purification project worth 64.425 million yuan [34] - Lihua Co. reported April sales revenue of 1.125 billion yuan from chicken sales [35]

丙戊酸钠注射用浓溶液是一种抗癫痫药，在成人和儿童中，当暂时不能服用 口服剂型时，用于替代口服剂型，主要用于治疗全身性发作，表现为失神性发作、 肌肉抽搐性发作、强直-阵挛性发作，以及局灶性和继发性全身性发作。 公司丙戊酸钠注射用浓溶液研发成功后已进行了多国注册申报，分别已在中 国、英国、德国、荷兰、葡萄牙、爱尔兰、西班牙、意大利、法国获得上市许可。 截至目前，公司已在沙特阿拉伯提交注册申请。 自愿披露公司产品获得境外上市许可的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688553 证券简称：汇宇制药 公告编号：2025-035 四川汇宇制药股份有限公司（以下简称"公司"）子公司 Seacross Pharma (Europe) Ltd.近期收到法国国家药品和保健品安全局、西班牙国家药品和健康产 品管理局分别核准签发的公司产品丙戊酸钠注射用浓溶液、注射用环磷酰胺的上 市许可。现将相关情况公告如下： 二、药品的其他相关情况 四川汇宇制药股份有限公司 （一）丙戊酸钠注射用浓溶液 （二）注射用环磷酰胺 注射用环 ...

四川汇宇制药股份有限公司 2024年年度股东大会会议资料 证券代码：688553 证券简称：汇宇制药 四川汇宇制药股份有限公司 2024年年度股东大会 会议资料 召开时间 2025年5月16日 四川汇宇制药股份有限公司 2024年年度股东大会会议资料 四川汇宇制药股份有限公司 2024 年年度股东大会文件 目 录 | 议案一、《关于公司<2024年度董事会工作报告>的议案》 | 7 | | --- | --- | | 议案二、《关于公司<2024年度监事会工作报告>的议案》 | 8 | | 议案三、《关于公司<2024年年度报告及其摘要>的议案》 | 9 | | 议案四、《关于公司<2024年度财务决算报告>的议案》 | 10 | | 议案五、《关于公司<2024年度利润分配预案>的议案》 | 11 | | 议案六、《关于续聘2025年度审计机构、内部控制审计机构的议案》 12 | | | 议案七、《关于公司2025年度董事薪酬的议案》 13 | | | 议案八、《关于公司2025年度监事薪酬的议案》 14 | | | 议案九、《关于使用部分闲置自有资金投资金融产品的议案》 15 | | | 附件1:2024 ...

证券代码：688553 证券简称：汇宇制药 公告编号：2025-034 四川汇宇制药股份有限公司 关于召开 2024 年度暨 2025 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于5月13日(星期二)16:00前通过四川汇宇制药股份有限公司（以 下简称"公司"）邮箱 ir@huiyupharma.com 将需要了解和关注的问题提前提 供给公司。公司将在说明会上对投资者普遍关注的问题进行回答。 公司已于 2025 年 4 月 26 日在上海证券交易所网站（www.sse.com.cn）披露 了公司 2024 年年度报告以及 2025 年第一季度报告，为便于广大投资者更全面深 入地了解公司 2024 年年度及 2025 年第一季度经营成果、财务状况等信息，公司 计划于 2025 年 5 月 14 日上午 10:30-11:30 举行 2024 年度暨 2025 年第一季度业 绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以线上文字互动形式召 ...